Please login to the form below

Not currently logged in
Email:
Password:

UCB extends agreement with Novartis

UCB Germany has made an agreement with Novartis to extend commercial rights in Germany for the cardiovascular medication Provas beyond 2011

UCB Germany, an affiliate of the Belgian biopharmaceutical company, has made an agreement with Novartis to extend commercial rights in Germany for the cardiovascular medication Provas (valsartan) beyond 2011. 

The company has also negotiated rights for the hypertension treatments Dafiro (valsartan and amlodipine) and Dafiro HCT (valsartan, amlodipine and HCT) and will also co-market  two new oral diabeties therapies Jalra (vildagliptin Icandra and vildagliptin + metformin).

Willy Cnops, vice president  of UCB and managing director of the German operation, said in a  statement: "We are extending our cardiovascular and metabolic product portfolio with the most attractive and innovative treatment options to date in line with UCB's ambitions to offer the best medicines to our patients."

25th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics